Perfect storm or long overdue reckoning?

The regulatory headlines feel relentless. CAA 2021. CAA 2026. Department of Labor PBM disclosure proposals and FTC enforcement actions.

From a distance, it looks like a perfect storm gathering over employer-sponsored healthcare. But this is not a sudden weather event. It is a structural shift, one that is rapidly bringing health plan governance in line with the fiduciary standards long applied to retirement plans.

The real question is not whether change is happening. It is whether employers will use the tools now being placed in their hands to push change faster.

The convergence is intentional, with four major forces intersecting at once: transparency reforms introduced under the Consolidated Appropriations Act of 2021, pharmacy benefit manager financial reforms under CAA 2026 along with broader compensation disclosure requirements, EBSA's proposed PBM fee disclosure rule and increasing Federal Trade Commission (FTC) scrutiny of PBM pricing practices. Individually, each measure advances transparency. Together, they signal something broader. Healthcare benefits are entering a new fiduciary era.

For decades, defined contribution plans have operated under clear expectations and fiduciary governance. However, health plans have historically operated without structured fiduciary governance and with limited visibility into vendor economics, compensation and financial incentives. This gap is closing. 

And with the CAA 2026 we are seeing a quiet but significant expansion. Although much attention has focused on rebate reform and spread pricing scrutiny, one of the most consequential changes in CAA 2026 is technical.

The amendment to ERISA §408(b)(2) reframes who qualifies as a "covered service provider." Disclosure obligations now hinge on services performed in connection with the plan, not how an entity describes itself (brokerage/consultant). If a vendor influences plan administration, vendor selection or plan spending, compensation disclosure is required. Function, not title is the big game changer. For employers, this reduces ambiguity. It applies broadly across covered service relationships. Once compensation disclosures are received, fiduciaries must determine whether it is reasonable.

EBSA's proposed PBM disclosure rule would require detailed reporting directly to plan fiduciaries, including manufacturer rebates and incentive payments, spread pricing revenue, pharmacy recoupments and affiliate or administrative compensation streams. The proposal also strengthens audit rights and reinforces the expectation that fiduciaries evaluate compensation under ERISA standards. At the same time, FTC enforcement actions targeting PBM pricing practices are adding another layer of scrutiny, bringing multi-agency oversight and increasing pressure on PBM business models.

Some expect these reforms to immediately reduce drug costs or dismantle entrenched pricing models. That is unlikely. Unfortunately, vendor contracts do not reset instantly and games still will be played. Financial incentives evolve gradually and market structures adjust over time.

Expecting immediate transformation is like trying to clear a snow-covered sidewalk with a hair dryer. You may expose a small patch of pavement, but the snow remains. Real impact requires scale and sustained pressure. It requires the snowblower.

Regulators have expanded the leverage available to employers in meaningful ways. New rules and proposals are providing broader rights to compensation disclosures, clearer audit authority, greater access to rebate and spread pricing data, and stronger statutory grounding for evaluating whether vendor fees are reasonable under ERISA. However, leverage that goes unused produces little change. If employers treat these reforms simply as compliance checkboxes, the underlying economics of the healthcare system may remain largely intact.

Instead, these developments should prompt employers to take a more active role in overseeing their health plans. That means proactively requesting and reviewing compensation disclosures, benchmarking rebate and fee arrangements, renegotiating contracts to ensure appropriate data access and audit provisions, formalizing pharmacy governance processes and documenting fiduciary deliberations. When employers move from passive recipients of vendor information to active fiduciaries managing plan assets and costs, incentives across the system begin to realign.

Transparency is becoming the baseline, with visibility into compensation streams and financial relationships increasingly expected rather than optional. Conflicts of interest are receiving greater scrutiny, and fiduciary accountability is expanding as regulators and courts expect employers to review, evaluate and document their decisions. The fiduciary rigor long applied to defined contribution plans is migrating into health benefits — and it is happening at a faster pace.

For plan sponsors already accustomed to the governance structure surrounding retirement plans, the framework will feel familiar. What is different is the context: healthcare benefits are now being viewed through the same fiduciary lens, bringing with them a new set of expectations, responsibilities and opportunities for oversight.

This moment can be viewed as regulatory burden — or governance opportunity. Employers that proactively establish structured oversight processes will be positioned to take control of cost, reduce liabilities and improve plan and participant outcomes. 

This does not represent chaos. It represents correction. Statutory scaffolding is in place. The disclosure mechanisms are expanding. The enforcement environment is tightening. With a caution that change will not happen overnight.

But employers willing to move from hair dryers to snowblowers — from passive oversight to disciplined governance — will accelerate the clearing. 

The regulatory convergence is not merely a storm to endure. It is a reckoning that invites leadership.